In vivo pharmacokinetic study of antibody conjugates

The National Institutes of Health (NIH) Office of Logistics and Acquisition Operations (OLAO) intends to award a sole-source, firm-fixed-price purchase order to Jackson Laboratory under solicitation 75N98026Q00528. This procurement, conducted under FAR 6.302-1, covers in vivo pharmacokinetic studies of antibody-lectin conjugates to support serum half-life predictions. The work requires a specific transgenic mouse strain, B6.Cg-Fcgrttm 1Dcr Prkdcscid Tg(FCGRT)32Dcr/DcrJ, and involves intravenous administration followed by ELISA-based measurements. Small businesses may submit capability statements by June 12, 2026, to demonstrate their ability to meet these technical and strain-specific requirements. Although the agency is planning a non-competitive award under FAR 6.302-1, this notice allows other parties to submit capability statements. This information helps the government determine if a competitive procurement is possible. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) requires pharmacokinetic (PK) studies to support the development of antiviral antibody-protein conjugates for HIV prevention. This work is managed by the Natural Products Chemistry Section within the Laboratory of Bioorganic Chemistry.